77 research outputs found
CRYOGLOBULIN MEDIATED KIDNEY DISEASE: HCV INFECTION, HISTOLOGICAL PATTERNS, ROLE OF RITUXIMAB. MONOCENTRIC REPORT
No full textWe present a retrospective monocentric analysis performed on 121 patients referred to Our Unit from 2000 to 2016 with evidence of cryoglobulinemia. According to Brouet classification type III was the most common cryoglobulinemia (48%), followed by type II (23%) and type I (6%); 10% were type II-III.. Based on clinical and laboratory data we confirm cryoglobulinemic syndrome with renal involvment as a prognostically unfavourable feature, with increased mortality and progression to end stage renal disease. Patients with mixed cryoglobulinemia had a similar outcome
Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care
No full textAuthor can archive publisher's pdf. Free via Creative Commons: CC-BENCHTOBEDSIDE-2.0. © 2012 BioMed Central Ltd
Infrastrutture sociali, innovazione sociale e culturale e mercato del lavoro
No full textStiamo per lanciare il nono programma quadro dell’Unione Europea per la ricerca e l’innovazione per il settennio 2021-2027, ed è utile distinguere con attenzione tra ricerca, sviluppo e innovazione. La ricerca produce conoscenze, che dapprima sono validate solo in linea teorica, ad esempio un principio attivo all’interno di una molecola. Lo sviluppo serve a verificare la conoscenza attraverso dei modelli, trasportando la realtà concet- tuale nella realtà del mondo fisico, ad esempio un principio attivo in un farmaco sotto sperimentazione. L’innovazione, infine, trasforma la conoscenza in valore, facendo sì che il prodotto sia messo sul mercato, venga accolto dai consumatori e abbia successo; nell’esempio fatto finora quando si mostra come un farmaco sia riconosciuto come sem- pre più efficace e venga prescritto a vantaggio della salute dei cittadini. Va detto, però, che l’innovazione non è solo tecnologia che diventa valore, è anche progettualità che migliora i servizi abbassandone i costi. In questo caso, abbiamo l’innovazione sociale e l’innovazione culturale. Fermiamo prima l’attenzione sull’innovazione sociale, che è stata codificata da più tempo, mentre solo adesso iniziamo a capire che non possiamo più permetterci di dare per scontata l’innovazione culturale, della quale è urgente comprendere le dimensioni, i processi e i prodotti (Pozzo et al. 2020)
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling
No full text: Erythropoietin (EPO), originally identified for its critical hormonal role in promoting erythrocyte survival and differentiation, is a member of the large and diverse cytokine superfamily. Recent studies have identified multiple paracrineautocrine functions of EPO that coordinate local responses to injury by maintaining vascular autoregulation and attenuating both primary (apoptotic) and secondary (inflammatory) causes of cell death. Experimental evidence also supports a role for EPO in repair and regeneration after brain and spinal cord injury, including the recruitment of stem cells into the region of damage. Tissue expression of the EPO receptor is widespread, especially during development, and includes the heart. However, it is currently unknown as to whether EPO plays a physiological function in adult myocardial tissue. We have assessed the potential protective role of EPO in vitro with adult rat cardiomyocytes, and in vivo in a rat model of myocardial infarction with reperfusion. The results show that EPO markedly prevents the apoptosis of cultured adult rat myocardiocytes subjected to 28 h of hypoxia (approximately 3% normal oxygen). Additional studies employing a rat model of coronary ischemia-reperfusion showed that the administration of recombinant human EPO (5,000 units/kg of body weight; i.p. daily for 7 days) reduces cardiomyocyte loss by approximately 50%, an extent sufficient to normalize hemodynamic function within 1 week after reperfusion. These observations not only suggest a potential therapeutic role for recombinant human EPO in the treatment of myocardial ischemia and infarction by preventing apoptosis and attenuating postinfarct deterioration in hemodynamic function, but also predict that EPO is likely a tissue-protective cytokine in other organs as well
Membro del Comitato di redazione della rivista Critica della Razionalità Urbanistica (CRU)
No full text
#875 Europe's Economic Health: 1963.
No full textParticipants include: Dr. N.R. Danielian, President of the International Economic Policy Association Mr. Charles A. Cerami, Foreign Editor, Kiplinger Publications, and author of Alliance Born of Danger Dr. Henry W. Briefs, Associate Professor of Economics, Georgetown University, and Director of the Graduate Program in Public Policy Economic
- …
